Blood markers for kidney damage in type 2 diabetes
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is looking at whether certain markers of inflammation in the blood can help detect or monitor kidney damage caused by type 2 diabetes. It compares these new markers with a well-known one (MCP-1) to see which might be more helpful for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have type 2 diabetes.
- Your kidney damage is caused by diabetes, not by another condition.
- Your kidney function is not severely reduced (eGFR is 30 or higher).
- You do not have an active infection, recent heart attack or stroke, cancer, or a blood or autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether two simple blood tests (a measure of insulin resistance and certain inflammation markers) can help predict how diabetic kidney disease will progress. If you have diabetes and early kidney problems, this might help your doctor better understand your condition.
This trial tests a new system to manage diabetic kidney disease across all stages. It is for people with type 2 diabetes who either have no kidney damage or have kidney damage confirmed by a biopsy.
This study looks at simple blood tests to see if certain markers of inflammation and platelet levels are different in people with diabetic kidney disease compared to healthy people. The results might help doctors find kidney problems earlier in people with type 2 diabetes.
This study looks at two blood markers in people with diabetic kidney disease to see if they relate to the condition. It may help doctors understand the disease better and could lead to better monitoring or treatment in the future.
This trial looks at two proteins in your blood (cathepsin S and chromogranin A) to see if they can help detect early kidney damage in people with type 2 diabetes. If they are useful, doctors might be able to find kidney problems earlier and start treatment sooner.
This study looks for early warning signs in blood or other samples (using a special lab approach) to detect kidney problems sooner in people with diabetes. It may help patients and clinicians identify kidney risk earlier and follow changes over many years.
Hear when a new Diabetic Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.